Capivasertib Plus Fulvestrant Approved for Patients With HR-Positive, HER2-Negative Breast Cancer

On November 16, 2023, the US FDA approved capivasertib plus fulvestrant for patients with previously treated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more PIK3CA/AKT1/PTEN-alteration, as detected by an FDA-approved test.

Access the full article to read more here.